International E-publication: Publish Projects, Dissertation, Theses, Books, Souvenir, Conference Proceeding with ISBN.  International E-Bulletin: Information/News regarding: Academics and Research

Stability-Indicating LC Method for the Determination of Epinastine in Bulk Drug and in Pharmaceutical Dosage Form

    ,

Author Affiliations

  • 1Department of Chemistry, Deogiri Science College, Aurangabad 431004, MS, INDIA

Res. J. Recent Sci., Volume 1, Issue (ISC-2011), Pages 281-288, (2012)

Abstract

A novel stability-indicating LC assay method was developed and validated for quantitative determination of epinastine in bulk drugs and in pharmaceutical dosage form in the presence of degradation products generated from forced degradation studies. An isocratic, reversed phase LC method was developed to separate the drug from the degradation products, using an YMC ODS A- C18 (250 mm x 4.6 mm, 5 µm) column, and 0.05% v/v trifluroacetic acid and acetonitrile (65:35 v/v) as a mobile phase. The detection was carried out at the wavelength of 220 nm. The epinastine was subjected to stress conditions of hydrolysis (acid, base), oxidation, photolysis and thermal degradation. Degradation was observed for epinastine in base, thermal and in 30% H2O2 conditions. The drug was found to be stable in the other stress conditions attempted. The degradation products were well resolved from main peak. The percentage recovery of epinastine was ranged from (99.57% to 100.25%). The developed method was validated with respect to the linearity, accuracy (recovery), precision, specificity and robustness. The forced degradation studies prove the stability indicating power of the method.

References

  1. Merck Index, Merck and Co, Inc, USA, 13th edn.,(2001)
  2. Oshima K., Kazuhito, Asano K., Kanai K., Suzuki M.and Suzaki H., Influence of epinastine hydrochloride,an H1-receptor antagonist, on the function of miteallergen-pulsed murine bone marrow-derived dendriticcells in Vitro and in vivo, Mediators of inflammation,(2009)
  3. Toyoda M., Nakamura M., Nakagawa H., Distributionto the skin of epinastine hydrochloride in atopicdermatitis patients, European J. of dermatology, 17(1)33-36, (2007)
  4. Kanai K., Asano K., Watanabe S., Kyo Y. and SuzakiH., Epinastine hydrochloride antagonism againstinterleukin-4-mediated T cell cytokine imbalance invitro, Int. Arch Allergy Immuno., 140, 43-52 (2006)
  5. Takahashi N., Aizawa H., Inoue H., Matsumoto K.,Nakano H., Hirose T., Nishima S., Hara N., Effects ofepinastine hydrochloride on cholinergic neuro-effectortransmission in canine tracheal smooth muscle, European Journal of Pharmacology, 358 (1) 55-61(1998)
  6. Fraunfelder F.W., Epinastine hydrochloride for atopicdisease, Drugs Today, 40 (8) 677-683 (2004)
  7. Ohtani H., Kotaki H., Sawada Y., Iga T., Quantitativedetermination of epinastine in plasma by highperformanceliquid chromatography, J. of Chrom. B:Biomedical Sciences and Applications, 683 (2) 281-284(1996)
  8. Vera-Candioti L., Olivieri A.C., Goicoechea H.C., Simultaneous multiresponse optimization applied toepinastine determination in human serum by usingcapillary electrophoresis, Anal Chim Acta, 595 (1-2)310-318, (2007)
  9. Ghisleni D.D., Steppe M., Elfrides E.S. Schapoval, Development and validation of Liquid chromatographicand ultraviolet derivative spectrophotometric methodsfor determination of epinastine hydrochloride in coatedtablets, Journal of AOAC International , 90(5) 1266-1271 (2007)
  10. Saleh O.A., El-Azzouny A.A., Badawy A.M. andAboul-Enein H.Y., A validated HPLC method forseparation and determination of epinastinehydrochloride enantiomers, Journal of LiquidChromatography and Related technologies, 33(3) 413-422 (2010)
  11. Basaveswara Rao M.V., Reddy B.C.K., Srinivas RaoT., and Kalyani P., Determination of epinastinehydrobromide assay by potentiometric method, Rasayan Journal of Chemistry, 2(2) 361-363, (2009)
  12. International Conference on Harmonization ofTechnical Requirements for Registration ofPharmaceuticals for Human Use, Stability testing ofNew Drug Substances and Products, QIA (R2), (2003)
  13. Drug Information Branch (HFD-210), Validation ofanalytical procedure: Methodology, Step 4 In ICHHarmonized Tripartite Guidelines Q2B. Center forDrug Evaluation and Research, Rockville, MD, (1996)
  14. ICH-Guidelines: Text on validation of analyticalprocedures., Q2 (R1)
  15. Bakshi M., and Singh S., Development of validatedstability-indicating assay methods critical review, J.Pharm. Biomed Anal., 28, 1011-1040 (2002).